ILLUMENATE Pivotal Post-Approval Study (PAS)

NACompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 18, 2013

Primary Completion Date

December 8, 2017

Study Completion Date

October 6, 2020

Conditions
Peripheral Artery Disease
Interventions
DEVICE

"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"

"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."

DEVICE

EverCross™ 0.035 PTA Balloon Catheter

The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).

Trial Locations (41)

10029

Mount Sinai Medical Center, New York

15009

Heritage Valley Health System, Beaver

15146

Metro Health Hospital, Wyoming

15232

University of Pittsburgh Medical Center, Pittsburgh

17043

Pinnacle Health Cardiovascular Institute, INC., Wormleysburg

19010

Wake Heart Research, Raleigh

22908

University of Virginia, Charlottesville

25304

CAMC Clinical Trial Center, Charleston

27607

Rex Hospital, Raleigh

28801

Mission Hospital, Asheville

30322

Emory University Hospital, Atlanta

30342

Northside Hospital, Atlanta

32504

Coastal Vascular and Interventional, Pensacola

32605

Cardiovascular Research of North Florida, Gainesville

33176

Baptist Cardiac and Vascular Institute, Miami

37403

University Surgical Associates, Chattanooga

37660

Wellmont Holston Valley Medical, Kingsport

37909

Premier Surgical Associates, Knoxville

39216

Jackson Heart Clinic, Jackson

43214

OhioHealth Research Institute, Columbus

43606

Jobst Vascular Institute, Toledo

44035

North Ohio Research LTD., Elyria

44195

Cleveland Clinic Foundation, Cleveland

46802

St. Joseph Hospital, Fort Wayne

49770

Cardiac & Vascular Research Center of Northern Michigan, Petoskey

50309

Central Iowa Hospital Corporation, Des Moines

53215

Aurora Health Care, Milwaukee

57117

Sanford Health Vascular Associates, Sioux Falls

60181

Advocate Health and Hospitals Corporation, Oakbrook Terrace

73120

Oklahoma Foundation for Cardiovascular Research, Oklahoma City

75231

Texas Health & Research Education Institution, Dallas

77030

University of Texas Health Science Center - Houston, Houston

79902

El Paso Cardiology Associates, El Paso

80538

Medical Center of the Rockies, Loveland

85364

Yuma Regional Medical Center, Yuma

90017

Good Samaritan Hospital - Los Angeles, Los Angeles

94538

Mission Cardiovascular Research Institute, Fremont

06510

Yale University School of Medicine, New Haven

08015

Deborah Heart and Lung Center, Browns Mills

Unknown

Medical University Graz, Graz

Hanusch Krankenhaus Wien, Vienna

All Listed Sponsors
lead

Spectranetics Corporation

INDUSTRY

NCT03421561 - ILLUMENATE Pivotal Post-Approval Study (PAS) | Biotech Hunter | Biotech Hunter